People in England with a type of chronic heart failure could benefit from a new treatment option. Our final draft guidance recommends finerenone for adults with chronic heart failure with preserved or mildly reduced ejection fraction.
Heart failure with preserved or mildly reduced ejection fraction happens when the left side of the heart doesn't fill properly with blood during the diastolic (filling) phase. This means the heart is unable to pump enough blood to meet the body’s needs.
Heart failure with preserved or mildly reduced ejection fraction means the reduction in blood pumped is smaller than for heart failure with reduced ejection fraction.
Heart failure can cause symptoms including breathlessness, fatigue and ankle swelling. People with the condition often need to be admitted to hospital and this can have a significant impact on their quality of life and independence. Many people with chronic heart failure also live with other long-term conditions, including chronic kidney disease, diabetes and high blood pressure, making treatment more complex.
Finerenone is a type of treatment called a mineralocorticoid receptor antagonist (MRA). Unlike other MRAs, finerenone is nonsteroidal and so may be used by more people.
Of the estimated 635,000 people in England who have heart failure, half have preserved or mildly reduced ejection fraction. There were around 100,000 hospitalisations in England for heart failure in 2023 to 2024, making it one of the leading causes of avoidable hospital admissions. We estimate up to 280,000 people could be eligible for finerenone.
We expect to publish our final guidance on finerenone in August 2026.
Excerpt from the official page. The original is authoritative.